• Explore /
  • Poster
  • / Effectiveness and safety outcomes in patients with EBV<sup>+</sup> PTLD treated with allogeneic EBV-specific T-cell immunotherapy (tabelecleucel) under an expanded access program (EAP) in Europe.

Effectiveness and safety outcomes in patients with EBV+ PTLD treated with allogeneic EBV-specific T-cell immunotherapy (tabelecleucel) under an expanded access program (EAP) in Europe.

Abstract Video & Slides Poster

Authors

Sylvain Choquet

Sylvain Choquet

Hôpital de la Pitié-Salpêtrière, Paris, France

Sylvain Choquet , Andrew Clark , Cécile Renard , Ben Uttenthal , Sridhar Chaganti , Ralf Ulrich Trappe , Patrizia Comoli , Xinyuan Duan , Baodong Xing , Charley Wu , Laurence Gamelin , Jan-Henrik Terwey , Anke Friedetzky , Daan Dierickx

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 7521)

DOI

10.1200/JCO.2023.41.16_suppl.7521

Abstract #

7521

Poster Bd #

72

Abstract Disclosures

Similar Posters

First Author: Stefanie Zschaebitz

First Author: Mason Webb

First Author: Paula Rodríguez-Otero

First Author: Mototsugu Oya